Long non-coding RNA HOTAIR drives EZH2-dependent myofibroblast activation in systemic sclerosis through miRNA 34a-dependent activation of NOTCH

Background Systemic sclerosis (SSc) is characterised by autoimmune activation, tissue and vascular fibrosis in the skin and internal organs. Tissue fibrosis is driven by myofibroblasts, that are known to maintain their phenotype in vitro, which is associated with epigenetically driven trimethylation of lysine 27 of histone 3 (H3K27me3). Methods Full-thickness skin biopsies were surgically obtained from the forearms of 12 adult patients with SSc of recent onset. Fibroblasts were isolated and cultured in monolayers and protein and RNA extracted. HOX transcript antisense RNA (HOTAIR) was expressed in healthy dermal fibroblasts by lentiviral induction employing a vector containing the specific sequence. Gamma secretase inhibitors were employed to block Notch signalling. Enhancer of zeste 2 (EZH2) was blocked with GSK126 inhibitor. Results SSc myofibroblasts in vitro and SSc skin biopsies in vivo display high levels of HOTAIR, a scaffold long non-coding RNA known to direct the histone methyltransferase EZH2 to induce H3K27me3 in specific target genes. Overexpression of HOTAIR in dermal fibroblasts induced EZH2-dependent increase in collagen and α-SMA expression in vitro, as well as repression of miRNA-34A expression and consequent NOTCH pathway activation. Consistent with these findings, we show that SSc dermal fibroblast display decreased levels of miRNA-34a in vitro. Further, EZH2 inhibition rescued miRNA-34a levels and mitigated the profibrotic phenotype of both SSc and HOTAIR overexpressing fibroblasts in vitro. Conclusions Our data indicate that the EZH2-dependent epigenetic phenotype of myofibroblasts is driven by HOTAIR and is linked to miRNA-34a repression-dependent activation of NOTCH signalling.

[1]  M. Manetti,et al.  The contribution of epigenetics to the pathogenesis and gender dimorphism of systemic sclerosis: a comprehensive overview , 2020, Therapeutic advances in musculoskeletal disease.

[2]  J. Nanchahal.  Faculty Opinions recommendation of PU.1 controls fibroblast polarization and tissue fibrosis. , 2020 .

[3]  D. Khanna,et al.  Inhibition of EZH2 prevents fibrosis and restores normal angiogenesis in scleroderma , 2019, Proceedings of the National Academy of Sciences.

[4]  Jiang-Feng Wu,et al.  The roles of lncRNA in hepatic fibrosis , 2018, Cell & Bioscience.

[5]  Wei Zhao,et al.  Long non-coding RNA HOTAIR overexpression improves premature ovarian failure by upregulating Notch-1 expression. , 2018, Experimental and therapeutic medicine.

[6]  W. Birchmeier,et al.  The tyrosine phosphatase SHP2 controls TGFβ-induced STAT3 signaling to regulate fibroblast activation and fibrosis , 2018, Nature Communications.

[7]  Pietro Laneve,et al.  Mir-34a-5p Mediates Cross-Talk between M2 Muscarinic Receptors and Notch-1/EGFR Pathways in U87MG Glioblastoma Cells: Implication in Cell Proliferation , 2018, International journal of molecular sciences.

[8]  F. Watt,et al.  Spatial and Single-Cell Transcriptional Profiling Identifies Functionally Distinct Human Dermal Fibroblast Subpopulations , 2018, The Journal of investigative dermatology.

[9]  P. Emery,et al.  Scleroderma fibroblasts suppress angiogenesis via TGF-β/caveolin-1 dependent secretion of pigment epithelium-derived factor , 2017, Annals of the rheumatic diseases.

[10]  H. Lan,et al.  Novel lncRNA Erbb4-IR Promotes Diabetic Kidney Injury in db/db Mice by Targeting miR-29b , 2017, Diabetes.

[11]  K. Song,et al.  Epigenetic Silencing of miRNA-34a in Human Cholangiocarcinoma via EZH2 and DNA Methylation: Impact on Regulation of Notch Pathway. , 2017, The American journal of pathology.

[12]  Richard A Young,et al.  The long noncoding RNA Wisper controls cardiac fibrosis and remodeling , 2017, Science Translational Medicine.

[13]  C. Feghali-Bostwick,et al.  The Mighty Fibroblast and Its Utility in Scleroderma Research , 2017, Journal of scleroderma and related disorders.

[14]  Wenjian Ma,et al.  Transcription of HOTAIR is regulated by RhoC-MRTF-A-SRF signaling pathway in human breast cancer cells. , 2017, Cellular signalling.

[15]  Hong Wang,et al.  Long non-coding RNA HOTAIR regulates proliferation and invasion via activating Notch signalling pathway in retinoblastoma , 2016, Journal of Biosciences.

[16]  Young Tae Kim,et al.  The long non-coding RNA HOTAIR increases tumour growth and invasion in cervical cancer by targeting the Notch pathway , 2016, Oncotarget.

[17]  B. Kahaleh,et al.  Epigenetics, the holy grail in the pathogenesis of systemic sclerosis. , 2015, Rheumatology.

[18]  V. Sondak,et al.  Phase 2 study of RO4929097, a gamma‐secretase inhibitor, in metastatic melanoma: SWOG 0933 , 2015, Cancer.

[19]  Jung-Eun Kim,et al.  Notch Intracellular Domain Expression in Various Skin Fibroproliferative Diseases , 2014, Annals of dermatology.

[20]  D. Khanna,et al.  Genome-wide DNA methylation analysis in dermal fibroblasts from patients with diffuse and limited systemic sclerosis reveals common and subset-specific DNA methylation aberrancies , 2014, Annals of the rheumatic diseases.

[21]  Xia Li,et al.  EZH2 expands breast stem cells through activation of NOTCH1 signaling , 2014, Proceedings of the National Academy of Sciences.

[22]  J. Rinn,et al.  Scaffold function of long non-coding RNA HOTAIR in protein ubiquitination , 2013, Nature Communications.

[23]  S. Balasubramanian,et al.  Binding Interactions between Long Noncoding RNA HOTAIR and PRC2 Proteins , 2013, Biochemistry.

[24]  C. Denton,et al.  Scleroderma pathogenesis: a pivotal role for fibroblasts as effector cells , 2013, Arthritis Research & Therapy.

[25]  S. Artavanis-Tsakonas,et al.  Notch signaling at a glance , 2013, Journal of Cell Science.

[26]  N. Brockdorff.  Noncoding RNA and Polycomb recruitment. , 2013, RNA.

[27]  Lorin E. Olson,et al.  Involvement of PDGF in Fibrosis and Scleroderma: Recent Insights from Animal Models and Potential Therapeutic Opportunities , 2013, Current Rheumatology Reports.

[28]  Karissa Y. Sanbonmatsu,et al.  Sizing up long non-coding RNAs , 2012, Bioarchitecture.

[29]  Yan Liu,et al.  EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations , 2012, Nature.

[30]  K. G. Guruharsha,et al.  The Notch signalling system: recent insights into the complexity of a conserved pathway , 2012, Nature Reviews Genetics.

[31]  M. Li,et al.  Characterization of the phenotype of high collagen‐producing fibroblast clones in systemic sclerosis, using a new modified limiting‐dilution method , 2012, Clinical and experimental dermatology.

[32]  B. Hinz,et al.  Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. , 2012, The American journal of pathology.

[33]  S. Miyano,et al.  Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. , 2011, Cancer research.

[34]  Rickard Sandberg,et al.  Notch signaling: simplicity in design, versatility in function , 2011, Development.

[35]  M. Mattson,et al.  Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis. , 2011, Arthritis and rheumatism.

[36]  Oliver Distler,et al.  Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis , 2011, Annals of the rheumatic diseases.

[37]  D. Reinberg,et al.  Phosphorylation of the PRC2 component Ezh2 is cell cycle-regulated and up-regulates its binding to ncRNA. , 2010, Genes & development.

[38]  Howard Y. Chang,et al.  Long Noncoding RNA as Modular Scaffold of Histone Modification Complexes , 2010, Science.

[39]  Howard Y. Chang,et al.  Long noncoding RNA HOTAIR reprograms chromatin state to promote cancer metastasis , 2010, Nature.

[40]  B. Pasche,et al.  Transforming growth factor β as a therapeutic target in systemic sclerosis , 2009, Nature Reviews Rheumatology.

[41]  E. Donadi,et al.  Affected and non-affected skin fibroblasts from systemic sclerosis patients share a gene expression profile deviated from the one observed in healthy individuals. , 2008, Clinical and experimental rheumatology.

[42]  Oliver Distler,et al.  Rho-associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts. , 2008, Arthritis and rheumatism.

[43]  R. Lafyatis,et al.  Cartilage oligomeric matrix protein expression in systemic sclerosis reveals heterogeneity of dermal fibroblast responses to transforming growth factor β , 2008, Annals of the rheumatic diseases.

[44]  Howard Y. Chang,et al.  Functional Demarcation of Active and Silent Chromatin Domains in Human HOX Loci by Noncoding RNAs , 2007, Cell.

[45]  C. Haass,et al.  A γ‐secretase inhibitor blocks Notch signaling in vivo and causes a severe neurogenic phenotype in zebrafish , 2002, EMBO reports.

[46]  U. Müller-Ladner,et al.  Digital Ulcers in Systemic Sclerosis - How to Manage in 2013? , 2013, Current rheumatology reviews.

[47]  G. Ganji,et al.  EZH 2 inhibition as a therapeutic strategy for lymphoma with EZH 2-activating mutations , 2012 .

[48]  H. Ihn,et al.  Increased expression of TGF-beta receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-beta signaling to scleroderma phenotype. , 1998, The Journal of investigative dermatology.

[49]  H. Ihn,et al.  Increased Expression of TGF-β Receptors by Scleroderma Fibroblasts: Evidence for Contribution of Autocrine TGF-β Signaling to Scleroderma Phenotype , 1998 .